Innoviva Gross Profit 2010-2024 | INVA

Innoviva gross profit from 2010 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Innoviva Annual Gross Profit
(Millions of US $)
2023 $268
2022 $318
2021 $392
2020 $337
2019 $261
2018 $261
2017 $217
2016 $134
2015 $54
2014 $8
2013 $5
2012 $6
2011 $25
2010 $24
2009 $24
Innoviva Quarterly Gross Profit
(Millions of US $)
2024-03-31 $67
2023-12-31 $73
2023-09-30 $57
2023-06-30 $72
2023-03-31 $66
2022-12-31 $56
2022-09-30 $64
2022-06-30 $108
2022-03-31 $90
2021-12-31 $108
2021-09-30 $98
2021-06-30 $101
2021-03-31 $86
2020-12-31 $90
2020-09-30 $89
2020-06-30 $79
2020-03-31 $79
2019-12-31 $76
2019-09-30 $66
2019-06-30 $64
2019-03-31 $55
2018-12-31 $80
2018-09-30 $62
2018-06-30 $67
2018-03-31 $52
2017-12-31 $70
2017-09-30 $49
2017-06-30 $59
2017-03-31 $40
2016-12-31 $44
2016-09-30 $33
2016-06-30 $32
2016-03-31 $24
2015-12-31 $23
2015-09-30 $14
2015-06-30 $11
2015-03-31 $7
2014-12-31 $7
2014-09-30 $1
2014-06-30 $1
2014-03-31 $-1
2013-12-31 $1
2013-09-30 $0
2013-06-30 $1
2013-03-31 $1
2012-12-31 $6
2012-09-30 $1
2012-06-30 $1
2012-03-31 $127
2011-12-31 $5
2011-09-30 $6
2011-06-30 $6
2011-03-31 $6
2010-12-31 $7
2010-09-30 $5
2010-06-30 $6
2010-03-31 $6
2009-12-31 $4
2009-09-30 $6
2009-06-30 $5
2009-03-31 $10
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.993B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $824.287B 119.14
Novo Nordisk (NVO) Denmark $642.884B 49.40
Johnson & Johnson (JNJ) United States $349.955B 13.90
Merck (MRK) United States $329.771B 60.00
AbbVie (ABBV) United States $293.293B 15.15
AstraZeneca (AZN) United Kingdom $248.255B 21.58
Novartis AG (NVS) Switzerland $215.744B 15.30
Pfizer (PFE) United States $156.738B 19.48
Sanofi (SNY) $122.543B 11.56